EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
Trial · NCT02635386
Results by group115
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 115
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Oral Disposition (Insulin Sensitivity-insulin Secretion) Index | Exenatide Once Weekly (EQW ) | 471 | Standard Error 83 | index score | |
| Oral Disposition (Insulin Sensitivity-insulin Secretion) Index | Dapagliflozin (DAPA) | 311 | Standard Error 90 | index score | |
| Oral Disposition (Insulin Sensitivity-insulin Secretion) Index | EQW Plus DAPA | 503 | Standard Error 80 | index score | |
| Oral Disposition (Insulin Sensitivity-insulin Secretion) Index | Dapagliflozin Plus Glucophage (MET ER) | 395 | Standard Error 85 | index score | |
| Oral Disposition (Insulin Sensitivity-insulin Secretion) Index | Phentermine /Topiramate (PHEN/ TPM) ER | 545 | Standard Error 93 | index score | |
| Absolute Body Weight | Exenatide Once Weekly (EQW ) | 100.4 | Standard Error 3.7 | kilogram | |
| Absolute Body Weight | Dapagliflozin (DAPA) | 102.6 | Standard Error 4 | kilogram | |
| Absolute Body Weight | EQW Plus DAPA | 99 | Standard Error 3.7 | kilogram | |
| Absolute Body Weight | Dapagliflozin Plus Glucophage (MET ER) | 101.2 | Standard Error 3.8 | kilogram | |
| Absolute Body Weight | Phentermine /Topiramate (PHEN/ TPM) ER | 97 | Standard Error 4.1 | kilogram | |
| Body Mass Index (BMI) | Exenatide Once Weekly (EQW ) | 37.3 | Standard Error 1.1 | kilogram/meter squared | |
| Body Mass Index (BMI) | Dapagliflozin (DAPA) | 37.4 | Standard Error 1.2 | kilogram/meter squared | |
| Body Mass Index (BMI) | EQW Plus DAPA | 36.7 | Standard Error 1.1 | kilogram/meter squared | |
| Body Mass Index (BMI) | Dapagliflozin Plus Glucophage (MET ER) | 37 | Standard Error 1.2 | kilogram/meter squared | |
| Body Mass Index (BMI) | Phentermine /Topiramate (PHEN/ TPM) ER | 35.3 | Standard Error 1.3 | kilogram/meter squared | |
| Change in Percent Body Weight | Exenatide Once Weekly (EQW ) | 3.8 | Standard Error 0.8 | percentage change in body weight | |
| Change in Percent Body Weight | Dapagliflozin (DAPA) | 1.5 | Standard Error 1.4 | percentage change in body weight | |
| Change in Percent Body Weight | EQW Plus DAPA | 6.9 | Standard Error 0.9 | percentage change in body weight | |
| Change in Percent Body Weight | Dapagliflozin Plus Glucophage (MET ER) | 1.7 | Standard Error 1.0 | percentage change in body weight | |
| Change in Percent Body Weight | Phentermine /Topiramate (PHEN/ TPM) ER | 8.1 | Standard Error 1.3 | percentage change in body weight |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02635386/results